Skip to content

Released Nov 13, 2023, after the close

10-Q filed Nov 13, 2023, 44 days after period end · 0000950170-23-063037

Q3 2023 · 10-Q
Revenue$16.92M−32.7% vs Q3 2022+62.5% vs Q2 2023
Net Income-$49.28MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.81N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$44,014,000N/M
Operating Cash Flowderived-$33,502,000N/M
Margins · derived
Operating margin-260.1%−175.7 pt vs Q3 2022
Net margin-291.2%−213.7 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$16.92M$25.15M$8.52M$17.82M
Net Income-$49.28M-$19.49M-$30.90M$17.14M
EPS Diluted-$0.81-$0.37-$0.67$0.45

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR